Sharma Nilesh Kumar, Sarode Sachin C, Sekar Gopinath, Sonawane Kaveri, Bomle Dhanashree
Cancer and Translational Research Lab, Dr. D. Y. Patil Biotechnology and Bioinformatics Institute, Pune, India.
Department of Oral Pathology and Microbiology, Dr. D. Y. Patil Dental College and Hospital, Dr. D. Y. Patil Vidyapeeth, Pune, India.
J Cancer Prev. 2024 Dec 30;29(4):105-112. doi: 10.15430/JCP.24.015.
Given the evolutionary nature of tumor complexities and heterogeneity, the early diagnosis of cancer encounters various challenges. Complexities at the level of metabolite reprogramming are compelling in the background of invasiveness, metastasis, drug- and radiation-induced metabolic alterations, immunotherapy-influenced changes, and pro-tumor niche including microbiome. Therefore, it is crucial to examine both current and future obstacles associated with early cancer detection specifically in the context of tumor metabolite biomarkers at preclinical and clinical levels. In conclusion, the significance of tumor metabolite biomarkers must be aligned with a comprehensive approach to achbieve diagnosis and prognosis of cancer patients by securing solutions to formidable challenges.
鉴于肿瘤复杂性和异质性的进化本质，癌症的早期诊断面临各种挑战。在侵袭、转移、药物和辐射诱导的代谢改变、免疫治疗影响的变化以及包括微生物群在内的促肿瘤生态位背景下，代谢物重编程水平的复杂性令人瞩目。因此，在临床前和临床水平上，特别是在肿瘤代谢物生物标志物的背景下，审视与早期癌症检测相关的当前和未来障碍至关重要。总之，肿瘤代谢物生物标志物的重要性必须与一种全面的方法相结合，通过解决巨大挑战来实现癌症患者的诊断和预后。
